Skip to content

Multicenter Randomized Double-Blind Controlled Study of Leucovorin Calcium in the Treatment of Autism Spectrum Disorder

Multicenter Randomized Double-Blind Controlled Study of Leucovorin Calcium in the Treatment of Autism Spectrum Disorder

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600122145
Enrollment
Unknown
Registered
2026-04-09
Start date
2026-04-10
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder

Interventions

Placebo group:The patients were given placebos in addition to their regular rehabilitation treatment.
Leucovorin Calcium low dose:On the basis of routine rehabilitation for enrolled patients, leucovorin calcium will be administered at 0.5 mg/kg/day, divided into two doses given in the morning and even
Leucovorin Calciummedium medium dose:On the basis of routine rehabilitation for enrolled patients, leucovorin calcium will be administered at 1.0 mg/kg/day, divided into two doses given in the morning
Leucovorin Calciummedium high dose:On the basis of routine rehabilitation for enrolled patients, leucovorin calcium will be administered at 2.0 mg/kg/day, divided into two doses given in the morning a

Sponsors

Maternity and Children Health Care Hospital of Luohu District
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 6 Years

Inclusion criteria

Inclusion criteria: 1. Male or female children aged 6 years or younger at the time of signing the informed consent form. 2. Meet the diagnostic criteria for autism spectrum disorder (ASD) in accordance with the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). 3. Parents or legal guardians have agreed to participate in this study and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Known hypersensitivity to any component of leucovorin calcium. 2. Uncontrolled epilepsy or convulsions. 3. Abnormal hepatic, cardiac or renal function. 4. Megaloblastic anemia caused by pernicious anemia or vitamin B12 deficiency. 5. Concomitant use of medications that may affect folate metabolism (e.g., methotrexate, pyrimethamine, sulfonamides, vitamin supplements). 6. Current participation in other interventional clinical studies. 7. Any other conditions that, in the investigator’s judgment, may compromise study compliance, safety evaluation or efficacy evaluation.

Design outcomes

Primary

MeasureTime frame
Wechsler Preschool and Primary Scale of Intelligence- Fourth Edition, WPPSI-?;Developmental Scale for Children's Psychological Behavior, Second Edition;Autism Behavior Checklist, ABC;Childhood autism rating scale, CARs;(Psychoeducational Profile - Third Edition, PEP-3);Autism Treatment Evaluation Checklist, ATEC;Adverse Reaction Information Scale;

Secondary

MeasureTime frame
Folate Metabolic Enzyme Genotype;Methyl Cycle Metabolites;

Countries

China

Contacts

Public ContactLi Li

Maternity and Children Health Care Hospital of Luohu District

1748852622@qq.com+86 196 0419 1344

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026